According to an update from Pulmatrix, the company has enough capital to fund development of its inhaled drug portfolio through the middle of 2017, and its plans over the next year and a half include the initiation of a Phase 1 trial of PUR1900 for the treatment of cystic fibrosis, and a pharmacokinetic bioequivalence study of PUR0200 for the treatment of COPD.
Pulmatrix CEO Robert W. Clarke said, “During the second quarter, we strengthened our balance sheet, became a publicly traded company listed on NASDAQ, strengthened our management and board, and continued to move our pipeline of inhaled treatments for pulmonary disease forward. Specifically, we announced our partnership with Mylan for the development of PUR0200, our branded generic bronchodilator for COPD, in Europe and that we are moving toward a clinical trial for PUR1900, our lead proprietary product, which could be the first inhaled anti-fungal for patients with cystic fibrosis.”
The company said that it intended to seek patents for its iSPERSE (inhaled Small Particles Easily Respirable and Emitted) platform. In July 2015, it announced two new US patents, bringing its total to 36.
Read the Pulmatrix press release.
